BioLargo

US: BLGO

$37.7m market cap

$0.23 last close

BioLargo has a number of subsidiaries and products focused on using iodine chemistry. CupriDyne is a product that is currently on the market for industrial odor control. The subsidiary Clyra Medical is a wound care company with an iodine-based irrigation solution and SkinDisc, a cell therapy for wounds. It is developing the AOS as a low-cost water purification device. Finally, the company has a full service environmental engineering team.

Investment summary

BioLargo reported combined annual revenue growth of 93% across all business units in Q319 to $0.53m. Both Odor-No-More and BioLargo Engineering Science and Technology (BLEST) divisions are expected to generate positive cash flow by YE19 or H120. Of note, a memorandum of understanding (MOU) was signed, possibly opening access to a new market, and positive results from BLEST’s PFAS-removal device was reported. Additionally, 510(k) market clearance was granted for the Clyra Wound Irrigation Solution.

Sector
Healthcare
Share price graph
Price performance
%
1m
3m
12m
Actual (14.8) 0.0 (11.5)
Relative* (15.8) (5.6) (23.3)
52-week high/low US$0.4/US$0.2
*% relative to local index
Key management
Dennis Calvert President & CEO